On June 28th, STENTiT was awarded first prize in the TERMIS European Business Plan Competition. After 2 intense pre-selection rounds, 5 out of 19 teams eventually made it to the finals and pitched in Davos, Switzerland. STENTiT was chosen as the winner of the competition due to the quality of the pitch, the technological approach[…]
We are very pleased to announce that STENTiT is one of the 5 finalists of the TERMIS-EU Business Plan Competition 2017. On Tuesday 27th of June around 17:15, we will present our business plan live on stage in room “A Davos” in Davos Switzerland. The winners will be announced later on Thursday June 29th. We[…]
This afternoon, dr. Sol Cabrera and dr. Sanders will present STENTiT during the short company presentation session at Biomedica 2017. In the spirit of euregional and international cooperation, the Biomedica Life Sciences Summit will bring together top researchers, innovators, and entrepreneurs from Belgium, Germany, and the Netherlands, and also from all over the globe. Its[…]
STENTiT is proud to announce that it has been selected among the top 10 European companies to participate in one of the largest start-up competitions in tissue engineering and regenerative medicine across Europe, the TERMIS-EU BPC. TERMIS is the world’s leading non-profit forum for academic and industrial developments within the fields of tissue engineering and[…]
STENTiT will present its regenerative stent approach at the Innovation for Health event on the 16th of February in Rotterdam, taking part of the Innovation Pitches afternoon session. Innovation for Health is the Netherlands´ premier conference for key players in Health and Life Sciences. It brings together key players and stakeholders who play decisive parts[…]
The STW Take-Off program has just closed their 5th round. STENTiT is very pleased to announce that its Take-Off Phase II application has been granted. The funding will be used to expand the R&D lines, proceed with translational studies and further grow the business. With this achievement we conclude 2016 which has been a very[…]
During the Dutch Life Sciences conference in Leiden, the founders of STENTiT pitched their business plan to a group of life science investors. Among the candidates, STENTiT was unanimously chosen by the jury as the winner of the Investors Forum. In addition, STENTiT presented the case in front of a large audience during the plenary[…]
The NanoNextNL valorization committee has approved to provide financial support to develop the STENTiT business case. NanoNextNL is the Dutch national research and technology programme for micro and nano technology.
The Venture Challenge is an initiative from LifeSciences@Work, designed for life science researchers with entrepreneurial aspirations. STENTiT was selected as one of the 5 participants after pitching the business case to an experienced jury panel. The aim of the program is to develop an idea into a solid business case during a 10-week educational program[…]
The Metropolitan Region Eindhoven provided financial support to STENTiT in the shape of the “Stimuleringsfonds” subsidy. This funding will enable a close collaboration with regional clinical and industrial partners, to further improve the regenerative stent technology. The goal of the subsidy is to support bright ideas by giving them the financial opportunity to enhance their[…]
STENTiT presented the preliminary results of their regenerative stent technology last Monday by Sol Cabrera and Bart Sanders, during the 10th anniversary Biomedica Summit event in Germany. The jury acknowledged the innovative approach and awarded a cash price for being the best poster presentation in the category Medtech/Care. With around 70 large and small exhibitors[…]
STENTiT obtained the first pre-seed grant from the STW Take-Off program. The goal is to initiate the development of a new type of biodegradable stent for pediatric applications. The Take-Off Grant helps academic entrepreneurs with their spin-off company to make the step from an idea to a first prototype. The Take-Off instrument includes two stages;[…]